Skip to main contentLast updated: 05-Nov-2026
Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Intestine Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
Most of what is new in small bowel cancer is in tests and medicines, not in the operation. The operation to remove the tumour with its lymph nodes has not changed, and it is still the main treatment that can remove the cancer for good.
The biggest change is the tumour test. A test called MMR or MSI decides whether an immunotherapy drug can be used, and it can also point to a family condition.
Other ideas, such as blood tests for leftover cancer and drugs aimed at one gene change, are still being studied. Ask what is proven and what is only promising.
For the full picture of how these cancers are treated here, read our small bowel cancer treatment page. This post sorts the news into what to act on, what to watch and what to ignore.
Small bowel cancer is rare, so one new paper can sound like a big change. In reality, a few things have changed, a few are being tested, and the core of treatment is steady.
| Area | What is happening | What it means for you today |
|---|---|---|
| Tumour testing | Testing the tumour tissue has become routine and is going deeper | Ask that every sample is tested for MMR or MSI |
| Immunotherapy | A firm role for one group of tumours | Helps only tumours with the MMR change |
| Medicine after surgery | Large studies are still awaited | The current plan is based on bowel cancer experience |
| Targeted drugs | Drugs aimed at a gene change are being tried | Used only in selected people, often within a trial |
| The operation | No change | Removal with nearby lymph nodes stays the core |
The next sections take these one by one. If you have a different type of tumour, such as a GIST or a neuroendocrine tumour, the plan is separate, and our post on tumour types and their tests explains why.
Because one result can change the medicine. After the tumour is removed or biopsied, the lab checks whether its repair system for DNA is working. This is called MMR testing.
If the family condition is suspected, close relatives may need checks of their own. The reason a tumour can run in a family is described in our post on risk factors.
People whose tumour is dMMR or MSI-high, and whose cancer has spread. For them, a drug that releases the immune system, such as pembrolizumab, is now an accepted choice.
| Tumour result | Position of immunotherapy |
|---|---|
| dMMR or MSI-high, spread to other parts | Accepted treatment, discussed first |
| MMR intact (the majority) | Not a standard choice; studied in trials, alone or with chemotherapy |
| Not yet tested | Test first, then decide |
Studies in small bowel cancer so far show that the benefit sits mostly in the dMMR group. Offering this drug to everyone would go beyond the evidence. How the choice fits with chemotherapy is explained in our post on treatment when the cancer has spread.
Not yet in the way patients would like. Large trials of chemotherapy after surgery are still awaited, so today’s advice is borrowed from bowel cancer and adjusted to each person.
The usual plan after an operation that removes the tumour is in our post on treatment when the tumour can be removed.
Some tumours carry a gene change that a drug can aim at. The idea is attractive, but for small bowel cancer most of it is borrowed from stomach and bowel cancer and not yet proven in this cancer.
Tumours shed tiny pieces of DNA into the blood. A test called ctDNA looks for them after surgery, hoping to find cancer that scans cannot see.
The idea is promising for bowel cancer. For small bowel cancer there is not yet proof that it should guide treatment. A result should not be used on its own to start or to withhold chemotherapy. At present it belongs in research, and a good doctor will tell you so.
The operation. Removing the affected bowel with nearby lymph nodes, or a Whipple operation for a tumour near the duodenum, is still the main treatment that can remove the cancer for good.
New medicines do not replace a good operation. They are added around it.
Two steps matter more than any new drug. Do the MMR test on every sample, and rule out intestinal tuberculosis before a cancer pathway begins.
A simple way to read the news is to sort each item by how well it is proven.
| Development | How well proven | Stance |
|---|---|---|
| MMR or MSI test on every tumour | Established | Act |
| Immunotherapy for dMMR tumours | Established | Act |
| HER2, RAS and BRAF tests in advanced disease | Emerging | Act where it is useful |
| Wider gene panel in advanced disease | Emerging | Act where available |
| HER2-directed drugs | Not yet proven in small bowel cancer | Watch, or join a trial |
| Large trials of medicine after surgery | Awaited | Watch |
| Immunotherapy for MMR-intact tumours | Early | Watch, or join a trial |
| ctDNA blood test | Research only | Watch |
| A change in the main operation | None | Ignore |
If you read something online that is not in this table, ask your doctor which row it belongs to.
Ask each of these plainly. A good team will answer in simple words and will not hurry you.
The main operation has not changed. What has changed is testing of the tumour and the medicines chosen from the result, mainly immunotherapy for one group of tumours.
A laboratory test on the tumour tissue that checks whether its DNA repair system works. The result decides whether immunotherapy can be used and may point to a family condition.
No. The benefit is mostly in tumours that lost the repair system, called dMMR or MSI-high, and whose cancer has spread. For other tumours it is studied in trials.
Large trials are still awaited. Doctors currently borrow from colon cancer care, usually offering it when lymph nodes are involved, and adjust the plan to each person.
A ctDNA test is being studied for this. It is not yet proven in small bowel cancer, so it should not be used alone to decide on chemotherapy.
If your tumour test points to a family condition such as Lynch syndrome, your doctor may advise genetic counselling and checks for close relatives.
Tuberculosis of the ileum can look like a cancer on a scan, and the treatment is completely different. Tests on tissue settle the question before a cancer plan begins.
For the full range of small bowel cancer care, start at the small bowel cancer treatment page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
Have you been told you have a small bowel cancer, and read that new drugs are coming? Dr Harsh Shah will go through your reports, say which tests your tumour needs, and explain what is proven today and what is still being tested. Call, or message on WhatsApp. Call +91-63555-64601 Ask on WhatsApp
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.